Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Down 55.4% in April

Avalon GloboCare Corp. (NASDAQ:ALBT – Get Free Report) was the recipient of a significant drop in short interest in April. As of April 30th, there was short interest totaling 413,675 shares, a drop of 55.4% from the April 15th total of 926,778 shares. Based on an average daily trading volume, of 1,653,442 shares, the short-interest ratio is presently 0.3 days. Currently, 6.6% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Avalon GloboCare in a report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Avalon GloboCare currently has an average rating of “Sell”.

Get Avalon GloboCare alerts:

View Our Latest Stock Report on Avalon GloboCare

Avalon GloboCare Trading Down 1.2%

Avalon GloboCare stock traded down $0.00 during trading on Friday, hitting $0.34. 6,092 shares of the company were exchanged, compared to its average volume of 4,959,861. The company has a market capitalization of $2.85 million, a P/E ratio of -0.10 and a beta of -0.04. The business’s 50 day moving average is $0.54 and its 200 day moving average is $1.00. Avalon GloboCare has a 52 week low of $0.21 and a 52 week high of $4.74.

Avalon GloboCare (NASDAQ:ALBT – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.49) earnings per share for the quarter.

About Avalon GloboCare

(Get Free Report)

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.

Further Reading

• Five stocks we like better than Avalon GloboCare
• 3 AI Data Center Stocks Worth Watching for Capital Rotation
• McDonald’s Is the Cheapest It’s Been in Years—Does That Make It a Buy?
• Karman: Defense Darling’s Outlook Strengthens After 40% Drop
• Aeluma’s Post-Earnings Dip Creates a Buying Opportunity

Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.